WASHINGTON — Unless Republicans abruptly change course in their plan to repeal and replace the Affordable Care Act, it appears the drug industry will dodge one of its most-feared bullets in health reform.
The House GOP plan that leaked last week did not include pharma-focused offsets — spending cuts or other cost savings — to pay for itself. Perhaps the biggest risk in this debate for drug makers, as STAT reported in December, had been the specter of any offsets targeting them.
